Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 79,372 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Adult Solid Neoplasm
Interventions: Ixabepilone, Pharmacological Study, Temsirolimus; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Healthy, Pressure Pain Threshold, Massage
Interventions: Moderately Painful Massage; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: Colesevelam hydrochloride, placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission
Interventions: Laboratory Biomarker Analysis, Lenalidomide; Other · Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 60 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: The Bronx, New York • Winston-Salem, North Carolina

Conditions: Healthy
Interventions: Nemtabrutinib, Itraconazole; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Non-Small-Cell Lung
Interventions: Canakinumab, Docetaxel, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 6
States / cities: Atlanta, Georgia • Kansas City, Missouri • The Bronx, New York + 3 more

Conditions: Melanoma
Interventions: LGX818; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Kidney Stones
Interventions: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 11
States / cities: Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more

Conditions: Chronic Hepatitis C
Interventions: BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Anaheim, California • Coronado, California • San Jose, California + 7 more

Conditions: Healthy
Interventions: PF-04634817 Placebo, PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Gastrointestinal Stromal Tumors
Interventions: Masitinib, Sunitinib; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Fevers, Pain
Interventions: Lubricant Instillation, Lidocaine Lubricant; Procedure · Drug
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: 2 Months to 2 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Volunteers
Interventions: INCB057643; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Interventions: Dapansutrile, Placebo Tablet; Drug · Other
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more

Conditions: Heart Failure
Interventions: LMI 1195; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Interventions: Temsirolimus, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 25
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 22 more

Conditions: Post Partum Hemorrhage
Interventions: Tranexamic acid, No intervention; Drug · Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Falls Church, Virginia

Conditions: Breast Cancer
Interventions: Paclitaxel, trastuzumab, Neratinib; Drug · Biological
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Pittsburgh, Pennsylvania • Morgantown, West Virginia

Conditions: Hepatitis C, Thalassemia
Interventions: Peginterferon Alfa-2a and Ribavirin, Ribavirin; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years to 44 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 3
States / cities: Oakland, California • New York, New York • Philadelphia, Pennsylvania

Conditions: Weight Loss, Obesity, Overweight
Interventions: ABT Weight Loss Intervention; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 14 Years to 19 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Interventions: CAB-ROR2-ADC, PD-1 inhibitor; Biological
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 30 more

Conditions: Prevention
Interventions: Tenofovir 1% vaginal gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Houston, Texas + 1 more

Conditions: Prostate Cancer
Interventions: Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC, Radical Prostatectomy; Biological · Procedure
Lead sponsor: Ashutosh Kumar Tewari; Other
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Sjogren's Syndrome, Keratoconjunctivitis Sicca
Interventions: Levocarnitine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

The Duration of Effects of Massage in Healthy Participants

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Struvite Stones Antibiotic Study

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

First In Human Study Of Increasing Oral Doses Of PF-04634817

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Lidocaine Lubricant in Pediatric Urethral Catheterization

A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Prevention of Postpartum Hemorrhage With Tranexamic Acid

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

Wellness Achieved Through Changing Habits (The WATCH Study)

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Pharmacokinetic and Pharmacodynamic Study of Tenofovir 1% Gel

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Levocarnitine for Dry Eye in Sjogren's Syndrome